Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
In this study, we sequenced the coding region of GJB4 in 13 unrelated erythrokeratodermia variabilis families without detectable mutations in GJB3.
|
12648223 |
2003 |
Erythrokeratodermia variabilis
|
0.670 |
Biomarker
|
disease |
BEFREE |
Mutations associated with EKV have been identified in the connexin (Cx) genes GJB3 (Cx31) and GJB4 (Cx30.3), however, several cases of EKV have been tested negative for mutations in these two Cx genes.
|
22266302 |
2012 |
Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
Erythrokeratodermia variabilis et progressiva (EKV-P) is caused by mutations in either the GJB3 (Cx31) or GJB4 genes (Cx30.3).
|
29570224 |
2019 |
Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
We recently identified mutations in either GJB3 or GJB4 genes, encoding respectively connexin 31 (Cx31) or 30.3 (Cx30.3), as causally involved in erythrokeratodermia variabilis (EKV), a mostly autosomal dominant disorder of keratinization.
|
14583444 |
2003 |
Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
The human GJB4 gene has been deduced in silico and a mutation in a family with erythrokeratodermia variabilis has been reported.
|
11933201 |
2002 |
Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
Apparently, the same GJB4 mutation may cause either an EKV or a PSEK phenotype.
|
19291775 |
2009 |
Erythrokeratodermia variabilis
|
0.670 |
GeneticVariation
|
disease |
BEFREE |
Erythrokeratodermia variabilis et progressiva (EKVP) is a genodermatosis with clinical and genetic heterogeneity, most often transmitted in an autosomal dominant manner, caused by mutations in GJB3 and GJB4 genes encoding connexins (Cx)31 and 30.3, respectively.In this issue, Boyden et al.
|
25964267 |
2015 |
hearing impairment
|
0.110 |
GeneticVariation
|
phenotype |
BEFREE |
These GJB4 variants should help to define the putative role of connexin 30.3 in both skin disorders and hearing impairment.
|
11933201 |
2002 |
Keratoderma, Palmoplantar
|
0.110 |
Biomarker
|
disease |
BEFREE |
Mutations in connexin 31 (GJB3) and connexin 30.3 (GJB4), implicated in previous reports of EKV, and connexin 26 (GJB2), implicated in palmoplantar keratoderma, were unlikely given the lack of shared homozygous haplotypes in the regions surrounding these genes.
|
15668823 |
2005 |
Dermatologic disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The skin disease erythrokeratoderma variabilis (EKV) has been shown to be associated with mutations in GJB3 and GJB4 encoding connexin (Cx)31 and Cx30.3, respectively.
|
16297190 |
2005 |
Dermatologic disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
These GJB4 variants should help to define the putative role of connexin 30.3 in both skin disorders and hearing impairment.
|
11933201 |
2002 |
Erythrokeratoderma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Erythrokeratoderma variabilis (EKV) is a rare disorder of cornification usually associated with dominant mutations in the genes GJB3 and GJB4, which code for connexin (Cx)31 and Cx30.3, respectively, and contribute to the formation of functional gap junctions in the epidermis.
|
21564177 |
2011 |
Erythrokeratoderma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The skin disease erythrokeratoderma variabilis (EKV) has been shown to be associated with mutations in GJB3 and GJB4 encoding connexin (Cx)31 and Cx30.3, respectively.
|
16297190 |
2005 |
Inherited hearing loss
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mutations in connexin genes including GJB2 (Cx26), GJB3 (Cx31), GJB4 (Cx30.3), GJB6 (Cx30) and GJA1 (Cx43) are responsible for various dermatological syndromes and/or inherited hearing loss, frequently showing overlapping phenotypes.
|
19416251 |
2009 |
Inherited hearing loss
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mutations in five gap junction genes, including GJB2 (Cx26), GJB3 (Cx31), GJB4 (Cx30.3), GJB6 (Cx30) and GJA1 (Cx43) are known to cause inherited hearing loss and/or disorders of the skin and its appendages, often giving rise to overlapping phenotypes.
|
15757815 |
2005 |
Nonsyndromic Deafness
|
0.020 |
Biomarker
|
disease |
BEFREE |
On the basis of the above results, it was hypothesized that GJB4 may be a genetic risk factor for the development of nonsyndromic hearing loss and the data from the present study can be used to direct the clinical evaluation and effectively manage the care of families of children with GJB4.
|
25333454 |
2015 |
Nonsyndromic Deafness
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest the variants of GJC3, GJB4, and GJB3 may be the common genetic risk factor, after variants of GJB2, for the development of nonsyndromic HL in Taiwan.
|
20593197 |
2010 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, we demonstrated that Gjb4-mediated Src activation enhanced chemoresistance of cancer cells toward gemcitabine and etoposide.
|
30177841 |
2019 |
Lung Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We found that Gjb4 expression was higher in lung tumors than normal tissues (p = 0.0026), and Gjb4 levels in blood buffy coat samples showed significant performance in diagnosing stage I-III (p = 0.002814) and stage IV (p < 0.0001) lung cancer.
|
30177841 |
2019 |
Malignant neoplasm of stomach
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
We used Progression-free survival Kaplan-Meier analysis and Western blot analysis to detect the expression of GJB4 in GC tissues and cells.
|
31692499 |
2019 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation.
|
30177841 |
2019 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Using syngeneic mouse model, we observed that Gjb4 was able to promote tumor growth.
|
30177841 |
2019 |
Skin Diseases, Genetic
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Erythrokeratodermia variabilis et progressiva (EKVP) is a genodermatosis with clinical and genetic heterogeneity, most often transmitted in an autosomal dominant manner, caused by mutations in GJB3 and GJB4 genes encoding connexins (Cx)31 and 30.3, respectively.In this issue, Boyden et al.
|
25964267 |
2015 |
Skin lesion
|
0.010 |
Biomarker
|
group |
BEFREE |
It has similar skin lesions as observed for EKV, including congenital hyperkeratosis and red patches of variable sizes, shapes, and duration.
|
15668823 |
2005 |
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression or knockdown of Gjb4 increased or decreased lung metastasis of syngeneic mice, respectively.
|
30177841 |
2019 |